Skip to main content
Clinical Trials/EUCTR2015-001344-11-FR
EUCTR2015-001344-11-FR
Active, not recruiting
Phase 1

Multinational, multicenter, prospective, long-term safety and efficacy follow-up study after Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for restoration of corneal epithelium in patients with limbal stem cell deficiency due to ocular burns (HOLOCORE-FU) - HOLOCORE F

Chiesi Farmaceutici S.p.A.0 sites75 target enrollmentMay 16, 2018

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
corneal lesions with associated moderate to severe limbal stem celldeficiency due to ocular burns
Sponsor
Chiesi Farmaceutici S.p.A.
Enrollment
75
Status
Active, not recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 16, 2018
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • All patients (adults and pediatrics) who completed the HOLOCORE
  • core study and who consent to roll over to the present extension
  • study at the end of the HOLOCORE follow\-up.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 5
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 59
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 11

Exclusion Criteria

  • No specific exclusion criterion is considered for this study, except for
  • patients dropping out from the HOLOCORE study or withdrawing

Outcomes

Primary Outcomes

Not specified

Similar Trials